ARF-BP1 as mediator of p53 dependent and independent tumor suppression
A novel target for cancer therapy ARF has tumor suppressor activity that is p53 independent Since ARF-BP1 interacts with ARF and p53 but not with Mdm2, it is a useful therapeutic target in tumors that lack Mdm2 activity
Assay for compounds that inhibit ARF-BP1 binding to p53 Inhibitors of ARF-BP1 binding to p53 can be further developed into potential broad spectrum cancer drugs Determination of ARF-BP1 status of tumors may have prognostic value where the cellular level of ARF-BP1 may inversely correlate with good prognosis ARF-BP1 could be used as a biomarker for pre-malignant tumors or for tumor staging and grading
The present invention identifies ARF-BP1, a novel ubiquitin ligase, as a critical mediator of p53- dependent and p53-independent tumor suppression functions of ARF. ARF-BP1 directly binds and ubiquitinates p53. Inactivation of ARF-BP1 stabilizes p53 ...
美國
